Fig. 2

A2AR expression levels are correlated with the extent of Ado-mediated immunosuppression. a Representative example and b cumulative data of the functional sensitivity (EC₅₀ of IFN-γ production) to Ado measured in distinct CD8⁺ T cell memory subsets after overnight stimulation by anti-CD3/CD28 beads in the presence of decreasing concentrations of Ado (n = 12). c Cumulative data of AdoR expression (i.e., ADORA2A (n = 22), ADORA2B (n = 22), ADORA1 (n = 10), and ADORA3 (n = 10)) measured by RNA flow in total CD8⁺ T cells. d Cumulative data of A2AR measured by RNA flow in distinct CD8⁺ T cell memory subsets (n = 16). e Correlation between A2AR expression measured by RNA flow and the Ado-mediated fold change in IFN-γ production in total CD8⁺ T cells. Spearman’s test, n = 9. f Cumulative data of the fold change in IFN-γ production by CD8⁺ T cells stimulated overnight with anti-CD3/CD28 beads in the presence of the indicated combinations of Ado, A2AR agonist (CGS 21680) and A2AR/A2BR antagonists (ZM 241385 and PSB 1115, respectively). g Cumulative data showing the fold change in IFN-γ production by CD8⁺ T cells stimulated overnight with virus-specific peptides in the presence of the indicated combinations of Ado and A2AR antagonist (ZM 241385) (n = 6). In all box charts, the 25th to 75th percentiles, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001. Wilcoxon and/or one-way ANOVA tests